Taivex announced that the latest clinical trial data for its novel anticancer drug candidate T-1101 has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the world’s most prestigious oncology conferences, ASCO received over 7,500 abstract submissions this year. The selection of T-1101 underscores the innovation and clinical relevance of the program and reflects growing international recognition for its potential.

T-1101 is a first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, developed specifically for the treatment of advanced solid tumors. By disrupting a key pathway involved in tumor cell proliferation, T-1101 offers a novel therapeutic strategy for difficult-to-treat cancers. The program’s scientific direction aligns closely with ASCO’s mission to promote innovation and improve outcomes in cancer care.

The accepted abstract presents result from the Phase I clinical trial, which demonstrated favorable safety and tolerability, along with preliminary signs of clinical activity. Taivex is currently preparing for global multi-center trials and is actively collaborating with international research institutions and clinical partners to accelerate the development of T-1101 and bring new hope to patients worldwide.